BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20250101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:\n\n\n\n\n\n\n\n\nDate: Thursday 21st October 2021\nTime: 12:00 - 13:00 BST\nSpeakers: Chrissie Fletcher \;(GSK)\, Claire Brittain&nb sp\;(UCB)\, \;Paul Terril \;(PT Stat Consulting)\, Anashua Banerji  \;(Cytel).\n\nWho is this event intended for? \;For anyone lookin g to learn more about Imposter Syndrome.\nWhat is the benefit of attending ? Learn from others who relate with Imposter Syndrome\; hear their experie nces and advice to overcome it.\nOverview\nDo you ever think:\n&ldquo\;I d on&rsquo\;t belong here\, I&rsquo\;m not as capable as they think I am&rdq uo\;... &ldquo\;I don&rsquo\;t deserve it\, I&rsquo\;m just lucky&rdquo\;. .. &ldquo\;I'm never good enough\, others are better&rdquo\;... &ldquo\;I& rsquo\;m a fraud\, I&rsquo\;ll get found out&rdquo\;?\nImposter Syndrome&n bsp\;is experienced by 70% of people and the feelings of self-doubt and in adequacy it promotes can hold us back from valuing our accomplishments and reaching our full potential.\nLearn from others in the PSI Community who also associate with Imposter Syndrome. They will discuss the topic\, give their own personal views and experiences and provide tips to beat it.\nReg istration\nRegistration for this webinar is free\, and is open to Members of PSI only.\nTo register for this event\, please click here.\nSpeaker det ails\n\n\n\n \n \n \n Speaker\n \n \n Biography\n \n \n \n \n \n Chrissie Fletcher \n (G SK)\n \n \n Chrissie is the Vice Presiden t of Development Statistics at GlaxoSmithKline.She has worked in the Pharm aceutical Industry for 30 years and has experience of developing and comme rcialising new medicines in a variety of clinical disease areas across all phases of clinical development. Chrissie is actively engaged in statistic al societies\, pharmaceutical trade associations and initiatives relating to the Pharmaceutical Industry such as driving innovation in clinical tria ls and sharing implementation experiences of ICH E9(R1) and adoption of th e new estimand framework.\n \n \n \n \ n \n Claire Brittain \n (UCB)\n \n \n Claire has worked in medical statistics for over 15 years with most of those years in early phase pharmaceuticals. She has worked at GSK\, Eli Lilly and UCB primarily in neuroscience and immun ology\, then more recently in COVID-19. Claire has a keen interest in tran slational and methodology studies and enjoys making statistics pragmatic a nd keeping science at the heart of any discussion.\n \n \n \n \n \n Paul Terril \n (PT Stat Consulting)\n \n \n After co mpleting his PhD in statistics Paul started his career working as a statis tician in the agrochemical industry before becoming a statistical trainer for SAS. He moved into the pharmaceutical industry in 2005 and worked for several CROs before becoming an independent consultant in 2020. Paul prima rily provides support to biotech and small pharmaceutical companies who la ck in-house statistical expertise.\n \n \n \n \n \n Anashua Banerji \n (Cytel)\ n \n \n Anashua Banerji has cross-functio nal experience of more than 11 years in mathematical modeling\, biostatist ics\, business strategy consulting and technology product management in he althcare. In her current role at Cytel\, Anashua is focusing on adaptive d esigns\, enrichment strategies\, and applications of data science to real world data to mine insights relevant for trial design and stake-holder dec ision-making.\n \n \n \n\n \; DTEND:20211021T120000Z DTSTAMP:20261013T165902Z DTSTART:20211021T110000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Careers - Lunch & Learn: Imposter Syndrome Session UID:RFCALITEM639275075421085582 X-ALT-DESC;FMTTYPE=text/html:Logo resized
\n
\n
\n
\n
\n
\n
\n
\n
\nDate: Thursday 21st October 2021
\nTime: 12:00 - 13:00 BST
\nSpeakers: Chrissie Fletcher \;(GSK)\, Claire Brittain \;(UC B)\, \;Paul Terril \;(PT Stat Consulting)\, Anashua Banerji \;(Cytel).
\n
\nWho is this event i ntended for? \;For anyone looking to learn more about Imposte r Syndrome.
\nWhat is the benefit of attending? Lear n from others who relate with Imposter Syndrome\; hear their experiences a nd advice to overcome it.\n

Overview

\n

Do you ever think:

\n< p>&ldquo\;I don&rsquo\;t belong here\, I&rsquo\;m not as capable as they t hink I am&rdquo\;... &ldquo\;I don&rsquo\;t deserve it\, I&rsquo\;m just l ucky&rdquo\;... &ldquo\;I'm never good enough\, others are better&rdquo\;. .. &ldquo\;I&rsquo\;m a fraud\, I&rsquo\;ll get found out&rdquo\;?

\n

Imposter Syndrome \;is experienced by 70% of people and the feelings of self-doubt and inadequacy it promotes can hold us back from valuing our accomplishments and reaching our full potential.

\n

Learn from other s in the PSI Community who also associate with Imposter Syndrome. They wil l discuss the topic\, give their own personal views and experiences and pr ovide tips to beat it.

\n

Registration

\n

Registration for thi s webinar is free\, and is open to Members of PSI only.
\nTo register for this event\, please cli ck here.

\n

Speaker details

\n\n
\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n

Speaker

\n 		\n

Biography

\n
\n

Chrissieedit
\n Chrissie Fletcher
\n (GSK)

\n 		\n

Chrissie is the Vice President of Development Sta tistics at GlaxoSmithKline.She has worked in the Pharmaceutical Industry f or 30 years and has experience of developing and commercialising new medic ines in a variety of clinical disease areas across all phases of clinical development. Chrissie is actively engaged in statistical societies\, pharm aceutical trade associations and initiatives relating to the Pharmaceutica l Industry such as driving innovation in clinical trials and sharing imple mentation experiences of ICH E9(R1) and adoption of the new estimand frame work.

\n
\n

Claireedit
\n Claire Brittain
\n (UCB)

\n 		\ n

Claire has worked in medical statistics for over 15 years with most of those years in early phase pharmaceuticals. She has worked at GSK\, Eli Lilly and UCB primarily in neuroscience and immunology\, then m ore recently in COVID-19. Claire has a keen interest in translational and methodology studies and enjoys making statistics pragmatic and keeping sci ence at the heart of any discussion.

\n
\n

Pauledit
\n Paul Terril
\n (PT Stat Consulting)

\n 		\n

After completing his PhD in statistics Paul started his career w orking as a statistician in the agrochemical industry before becoming a st atistical trainer for SAS. He moved into the pharmaceutical industry in 20 05 and worked for several CROs before becoming an independent consultant i n 2020. Paul primarily provides support to biotech and small pharmaceutica l companies who lack in-house statistical expertise.

\n
\n

Anashuaedit
\n Anashu a Banerji
\n (Cytel)

\n 		\n

Anashua Banerji has cross-functional experience of more than 11 years in mathemati cal modeling\, biostatistics\, business strategy consulting and technology product management in healthcare. In her current role at Cytel\, Anashua is focusing on adaptive designs\, enrichment strategies\, and applications of data science to real world data to mine insights relevant for trial de sign and stake-holder decision-making.

\n
\n

 \;

END:VEVENT END:VCALENDAR